معرفی
Kimberly A. Kelly, Ph.D., is a Professor of Biomedical Engineering at the University of Virginia, affiliated with the School of Engineering and Applied Science. Her work focuses on developing targeted therapies and diagnostic tools for pancreatic ductal adenocarcinoma (PDAC) and other cancers using computational methods, bioinformatics, and nanotechnology. She holds tenure and leads the Kelly Lab, which integrates chemical biology, proteomics, and molecular imaging to identify druggable targets and improve drug delivery systems.
Education:
- B.A. Chemistry, Hamilton College (NY)
- Ph.D. Oncological Sciences, University of Utah (2002)
Research Interests: Pancreatic cancer, tumor microenvironment, drug development, targeted drug delivery, plectin protein biology, and molecular imaging. Her lab uses functional screening, AI, and bioinformatics to identify clinically relevant biomarkers and develop therapies with reduced toxicity.
Scientific Awards:
- William Guy Forbeck Scholar (2005)
- AACR-Pancreatic Cancer Action Network Career Development Award (2007)
- American Institute for Medical and Biological Engineering (AIMBE) Fellow (2016)
Grants & Projects: Dr. Kelly’s lab has secured funding for projects like the development of plectin-targeted therapies and imaging agents. Notably, her startup, ZielBio, received $25M to advance ZB131, a novel antibody targeting cancer-specific plectin (CSP). Her work on FAPi PET imaging and VCAM-1 targeted agents has bridged preclinical and clinical applications.
Labs/Teams: The Kelly Lab collaborates with institutions like MGH and focuses on translational research. Recent milestones include a first-in-human trial of ZB131 and serving as Editor-in-Chief of Molecular Imaging and Biology.
